Title : Clinical management of inflammatory bowel disease in the organ recipient.

Pub. Date : 2014 Apr 7

PMID : 24707135






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Active IBD at the time of LT, discontinuation of 5-aminosalicylic acid or azathioprine at the time of LT and use of tacrolimus-based immunosuppression may be associated with an unfavorable outcome of IBD after LT. Anti-tumor necrosis factor alpha (TNFalpha) therapy for refractory IBD may be an effective and safe therapeutic option after LT. Tacrolimus tumor necrosis factor Homo sapiens